INTRODUCTION
It is now common to screen infants for congenital adrenal hyperplasia by measuring levels of the precursor 17-hydroxyprogesterone (17-OHP) in the first week of life. Preterm infants have previously been shown to have elevated levels of 17-OHP.
1,2 Bronchopulmonary dysplasia, a common morbidity of prematurity, has also been independently linked to elevated levels of 17-OHP 3 and low levels of cortisol. 4 It is hypothesized that immaturity of adrenal gland steroidogenesis leads to a decrease in cortisol synthesis and an increase in cortisol precursors. 3 Similar to chronic lung disease, neonatal brain injury has been associated with inflammatory conditions such as maternal infection, placental inflammation, and postnatal leukocytosis. [5] [6] [7] [8] Thus, an altered response to perinatal inflammation may increase the risk of neonatal brain injury. The association between 17-OHP and neonatal brain injury has not been extensively investigated. Alterations in other hormones such as thyroxin (low levels in the case of serum T 4 ) have been consistently associated with mortality, 9 as well as intraventricular hemorrhage (IVH), 9 periventricular leukomalacia, 10 and cerebral palsy. 11 Both T 4 and 17-OHP are under control of the hypothalamic-pituitary axis and hypothyroxinemia in preterm infants has been suggested to be a result of hypothalamic-pituitary immaturity. 12 Alterations in levels of T 4 and 17-OHP have both been associated with factors such as gestational age and illness severity, [13] [14] [15] suggesting that abnormal levels of these hormones may be a marker for illness rather than an important part of the causal pathway.
In this investigation, we studied 17-OHP levels, obtained as part of routine state screening, in relation to the outcomes of death and IVH in a cohort of very low birth weight (VLBW) infants. We also investigated the relationship between 17-OHP and T 4 in the study sample. We hypothesized that infants who die and/or have severe IVH would have higher levels of 17-OHP compared to infants who survive without severe IVH.
METHODS
The study sample included a cohort of infants with birth weights <1500 g who were born during a 1-year period from July 1, 2001 to June 30, 2002. The Institutional Review Board of Christiana Care Health Services approved the project. Infants were included in the analysis if they had a minimum of one cranial sonogram performed and a minimum of one blood specimen obtained for newborn screening, n ¼ 134. All infants were cared for in the Special Care Nursery at Christiana Hospital, Newark, DE. The Special Care Nursery at Christiana Hospital is a level 3 nursery serving as a regional referral center for both inborn (90%) and outborn infants.
Infants in the study sample had blood drawn on the fifth day of life for 17-OHP and T 4 as part of the State of Delaware Newborn Screening Program. Infants had a repeat screen measured at 2 to 4 weeks of age. Infants in the study sample had a cranial sonogram on the fourth day of life and then monthly until hospital discharge. Cranial sonograms were obtained through the anterior fontanel using a 7.5 MHz transducer. Cranial sonograms were interpreted by a pediatric radiologist who was not aware of the results of the newborn screening. No infants in this investigation received supplemental thyroid hormone. For the purposes of this study, infants were considered to have hypotension as defined by protocol in the Special Care Nursery at Christiana Hospital. This protocol considers a mean arterial blood pressure equal to an infant's gestational age to be the lower limit of normal. Infants with hypotension are treated in a stepwise fashion.
Hypotension is first treated with slowly infused boluses of normal saline, up to 20 ml/kg. Dopamine is added if an infant's blood pressure fails to respond to colloid infusion. Dobutamine is added if an infant's blood pressure fails to respond to both colloid and dopamine. Infants in the study sample received hydrocortisone after birth, at the discretion of the attending neonatologist, for hypotension unresponsive to a combination of fluid administration and vasopressor support. No infants received supplemental steroids based on the results of 17-OHP testing.
The first newborn screen blood specimen was collected either by heel stick or from venous sampling when blood was needed for other studies. In the neonatal intensive care unit, blood for newborn screening is preferably collected on the fifth day of life. Repeat specimens are obtained at 2 to 4 weeks of life. All specimens are tested for total T 4 by radioimmunoassay in groups of 60. T 4 data are reported in mg/dl. To convert to nmol/l, values can be multiplied by 12.87. All specimens with total T 4 r3.5 mg/dl are repeated and tested for TSH by radioimmunoassay. Specimens with total T 4 >3.5 mg/dl are sorted by T 4 result and the lowest 10th percentile are selected for TSH testing. 17-OHP was measured by ELISA in the state of Delaware Newborn Screening Laboratory.
SNAP scores were calculated based on data from the first 24 hours of life as originally described by Richardson et al. 16 For the purpose of this investigation, IVH was classified as described by Papile et al. 17 Severe IVH was considered as grade III to IV. Gestational age was based on the best obstetrical estimate. Modified Ballard examination was used only if an obstetrical estimate was not available. 18 The attending obstetrician diagnosed clinical chorioamnionitis based on fever, uterine tenderness, or foulsmelling amniotic fluid. Infants were classified as receiving prenatal steroids if their mothers received any prenatal steroids prior to birth.
Statistics
Statistical analysis included Pearson correlation for two continuous variables, and w 2 for categorical variables. ANOVA was used for continuous variables. Since the 17-OHP data were not normally distributed, 17-OHP values were log transformed for analyses. However, data in the univariate analysis are presented as mean±SD to correspond to values reported to clinicians. Forward stepwise linear regression was performed to establish variables independently associated with levels of 17-OHP. Logistic regression was used to account for potentially confounding variables in determining the main outcomes of death and/or severe IVH. Data entered into the models include variables with a p<0.15 on univariate analysis or known confounders. A p-value <0.05 was considered significant. Statistical calculations were performed on commercially available software (Statistica, Tulsa, OK).
RESULTS
The study sample included 134 infants who had a cranial sonogram and a blood sample obtained for newborn screening. In the study sample, a second newborn screening sample was sent and available on 120 (90%) infants. By study definition, all infants had a minimum of one cranial sonogram performed. The median number of cranial sonograms carried out in the study population was 2.0 (mean 2.5±1.4). The first newborn screen was sent on a median of day 5 (mean 4.9±0.9 days). The second screen was sent on a median of day 20 (mean 21.4±8.4 days). None of the infants in the study sample was diagnosed with congenital adrenal hyperplasia or congenital hypothyroidism. During the study period, 38 infants died before they received a newborn screen for 17-OHP and T 4 on the 5th day of life, and therefore could not be included in the analysis.
Levels of 17-OHP were higher at the time of the first screen compared to the second screen (28.3±25.6 vs 17.0±18.0 ng/ml, p ¼ 0.01), respectively. Conversely, levels of T 4 were lower on the first screen compared to the second screen (7.1±4.2 vs 8.9±4.7 mg/dl, p<0.01), respectively.
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At the time of the first screen, levels of 17-OHP were correlated with SNAP, and inversely correlated with gestational age, birth weight, and T 4 ( Table 1) . At the time of the second screen, 17-OHP was again inversely correlated with gestational age and T 4 , and positively correlated with SNAP. 17-OHP was not correlated with birth weight on the second screen (Table 1) . 17-OHP levels on the first screen were significantly correlated with levels of 17-OHP on the second screen (Table 1) .
There was no effect of gender or race on 17-OHP (Table 2 ). However, infants of mothers who received antenatal steroids had elevated levels of 17-OHP on the first screen compared to infants born to mothers who did not receive steroids. Infants who had hypotension requiring dopamine support, hypotension requiring hydrocortisone support for blood pressure, and those infants born to mothers with clinical chorioamnionitis had elevated levels of 17-OHP on the first screen. Hypotension requiring dopamine support was the only variable that remained associated with elevated levels of 17-OHP on the second screen.
After controlling for potential confounding variables, gestational age, prenatal steroids, and T 4 were all independently associated with 17-OHP on the first screen (model: r 2 ¼ 0.39, p<0.01) and the second screen (r 2 ¼ 0.22, p<0.01). SNAP and clinical chorioamnionitis were not independently associated with levels of 17-OHP on either screen after controlling for confounding variables. Hypotension requiring dopamine and/or hydrocortisone were not included in these models because of the strong possibilities that altered levels of 17-OHP were part of the causal pathway of hypotension. 19 After controlling for gestational age, prenatal steroids, and clinical chorioamnionitis, neither 17-OHP levels on the first or second screen were associated with death (n ¼ 12), severe IVH (n ¼ 19), or the outcome of death and/or severe IVH (n ¼ 27) ( Table 3) . SNAP was not added to these models because of the strong possibility that 17-OHP affects illness severity. 15 Thus, illness severity may be an important intermediate variable in the causal pathway in final outcomes such as death and IVH. 19 The models were also run after excluding infants who had hypotension requiring hydrocortisone support. The results were unchanged after these analyses (data not shown).
DISCUSSION
Our study shows that VLBW infants have levels of 17-OHP that are inversely correlated with gestational age. Other factors such as prenatal steroids and low levels of T 4 are also independently associated with elevated levels of 17-OHP following birth. However, Paul et al.
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in our population of VLBW infants, elevated levels of the cortisol precursor 17-OHP are not associated with the outcome of death and/or severe IVH. IVH, the most common form of brain injury in preterm infants, has been associated with antenatal infections such as chorioamnionitis 5 and a postnatal leukocytosis 8 suggesting an inflammatory component to the pathophysiology of IVH. A similar association has been made between postnatal lung injury and antenatal inflammation. 20, 21 Moreover, low levels of cortisol in the postnatal period have been associated with other neonatal morbidities such as chronic lung disease. 4, 22 In this investigation, we hypothesized that infants who die and/or have severe IVH would show an elevation in 17-OHP, which is a precursor of cortisol. However, after controlling for the effects of gestational age and antenatal steroids we could show no independent association between severe IVH, mortality, and levels of 17-OHP. As we and others have recently studied the association of T 4 with mortality and brain injury, we did not address these associations in this study. 9, 10 After controlling for potential confounding variables, low levels of T 4 were associated with high levels of 17-OHP in our population of VLBW infants. These data could indicate that the production pathways of T 4 and 17-OHP in preterm infants are influenced by common factors. Alternatively, 17-OHP and T 4 may have some interactive, interdependent, or synergistic effect on each other. Both thyroxine and cortisol are important for controlling metabolic rate as well as the reabsorption of lung liquid following birth. 23 Consequently, if these two hormones are interactive, clinical trials of hormone replacement in preterm infants may have to address both the cortisol and thyroid hormone pathways. However, a recent randomized study of replacement of both hydrocortisone and T 3 showed no improvement in mortality or ventilatory requirement in infants less than 30 weeks gestation receiving hormone replacement. 24 Our study shows that antenatal steroids, independent of the effect of gestation, are associated with elevated levels of 17-OHP following birth. King et al. 25 have previously shown no relationship between antenatal steroid and postnatal 17-OHP. However, King et al. studied a cohort of more mature preterm infants, including infants up to 2500 g. King et al. 25 also relied on the birth hospital marking a check box on the birth certificate for steroid use and reported only an 8% use of steroids, suggesting an under-reporting of antenatal steroid use. Antenatal steroids have previously been shown to reduce fetal cortisol levels. 26 One explanation, for our finding of increased levels of 17-OHP following birth in infants whose mothers received steroids, is that antenatal steroids may inhibit or provide negative feedback on enzymes such as 21-hydroxylase or 11-b-hydroxylase, lead to the conversion of 17-OHP to cortisol. This is consistent with previous research suggesting decreased activity of 11-b-hydroxylase in extremely low birth weight infants. 2 Our investigation has a number of important limitations. Owing to the large standard deviation of 17-OHP levels, our data are log transformed. Our multivariate logistic regression models were thus limited in power because the outcomes studied were investigated only in relation to a one-fold log increase in 17-OHP. Smaller increases in 17-OHP, associated with death and/or IVH, would not have been detected in our study. Furthermore, 17-OHP was not measured in infants who died prior to the fifth day of life. Therefore, our study would not have been able to detect any possible association between early death, prior to the 5th day of life, and adrenal insufficiency. As we used data obtained as part of the routine state of Delaware screening, we did not measure cortisol, which is the metabolically active final product of steroidogenesis. Consistent with other investigations, 2 our data suggest that infants of low gestation have difficulty in converting 17-OHP to cortisol. Further study is needed on larger populations to explore the relationship between cortisol, death, and severe IVH.
As it is now common in many states to measure 17-OHP following birth, our data have important implications for clinicians. Our data show that factors such as gestational age and antenatal steroids must be taken into account when interpreting 17-OHP levels following birth in preterm infants. Since there was no association between IVH and mortality with 17-OHP levels, our data do not suggest therapeutic intervention based on levels of 17-OHP following birth.
